八大胜:Corporate Overview
八大胜:Development History
八大胜:Corporate Culture
八大胜:About Founder
八大胜:Core Team
八大胜:R&D Platform
Process Development
八大胜:Press Releases
Talent Concept
Richard Liqun Wang: China's Cell and Gene Therapy Poised to Take the Lead
Press Releases
2024-09-09
Dr. Richard Liqun Wang, Founder, Chairman, and CEO of Neukio Biotherapeutics, presented the current state, trends, bottlenecks, and prospects of Cell and Gene Therapy (CGT) research and development in China.
See More
Richard Wang: A Seventeen-Year Odyssey of an Overseas PhD Returnee in the Pursuit of Domestic Innovative Drug Development
八大胜:2024-02-23
Entrepreneur's insight: Innovation poses a formidable challenge that requires significant dedication and hard work. The complexities involved in this endeavor are often underestimated. To become a successful entrepreneur, it is crucial to have a clear goa
八大胜:See More
Neukio Biotherapeutics completed Series A-1 financing, to accelerate discovery and development of next generation cell therapy products
八大胜:2022-09-02
The funds raised will play important roles in accelerating the preclinical and clinical validation of induced pluripotent stem cell (iPSC)-derived off-the-shelf CAR-NK cell therapy products, and supporting team recruitment and expansion.
Neukio Biotherapeutics has completed $40m Angel round of financing and is committed to developing new NK technology platform and products
八大胜:2021-10-25
Neukio Biotherapeutics, a newly established company, recently announced the completion of its $40m Angel round of financing led by Lilly Asia Venture (LAV), with the participation of IDG Capital and Sherpa Investments. The fund will be used mainly for th
【Reprinted from Han Kun Law Offices】China Pilots Lifting Restrictions on Foreign Investment in Stem Cell, Gene Therapy, and Genetic Diagnosis Sectors in Four Free Trade Zones
八大胜:2024-09-24
八大胜:2024-09-09
Neukio Biotherapeutics and Tofflon Life Sciences Successfully Deliver Customized Glass Bioreactors
八大胜:2024-07-19
<dd id='JU3PV'><tbody id='6wa7T'><td id='myPyq'><optgroup id='3u5tT'><strong id='bgzh6'></strong></optgroup><address id='Irh6Y'><ul id='d8C4K'></ul></address><big id='FK4lj'></big></td><table id='QiaU7'></table></tbody><pre id='yPwgk'></pre></dd><span id='a4mVi'><b id='DvVUm'></b></span>
<dfn id='Dprk9'><optgroup id='6cuFM'></optgroup></dfn><tfoot id='Osp2q'><bdo id='UUABu'><div id='KgkXQ'></div><i id='hlB9s'><dt id='ukSIg'></dt></i></bdo></tfoot>
<ul id='wi8wt'></ul>
<fieldset id='EOEk4'></fieldset>
